HealthDay News — In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine, updated ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...

DOI: 10.1136/bmj-2024-080409 Meng-Ting Wang et al, Environmentally friendly inhaler regimens for COPD, BMJ (2024). DOI: 10.1136/bmj.q2825 ...

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

Black Americans have a higher likelihood of having asthma-COPD overlap syndrome (ACOS) but may not know it. Here’s what you ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

And according to the WHO, COPD is the fourth leading cause of death worldwide ... “WIN378, with its best-in-class potential to provide effective treatment through a six-month dosing regimen, could ...

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.